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Fabry disease is a rare X-linked hereditary disease caused by mutations in the AGAL gene encoding the lysosomal
enzyme alpha-galactosidase A. Enzyme replacement therapy (ERT) is the current cornerstone of Fabry disease
management. Involvement of kidney, heart and the central nervous system shortens life span, and fibrosis of these
organs is a hallmark of the disease. Fibrosis was initially thought to result from tissue ischemia secondary to
endothelial accumulation of glycosphingolipids in the microvasculature. However, despite ready clearance of
endothelial deposits, ERT is less effective in patients who have already developed fibrosis. Several potential
explanations of this clinical observation may impact on the future management of Fabry disease. Alternative
molecular pathways linking glycosphingolipids and fibrosis may be operative; tissue injury may recruit secondary
molecular mediators of fibrosis that are unresponsive to ERT, or fibrosis may represent irreversible tissue injury that
limits the therapeutic response to ERT. We provide an overview of Fabry disease, with a focus on the assessment of
fibrosis, the clinical consequences of fibrosis, and recent advances in understanding the cellular and molecular
mechanisms of fibrosis that may suggest novel therapeutic approaches to Fabry disease.
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Fabry disease is a rare X-linked hereditary disease caused
by mutations in the GLA gene encoding the lysosomal
enzyme alpha-galactosidase [1]. Males with classical dis-
ease are severely affected, while in females the random
inactivation of one X chromosome underlies a wide
spectrum of severity [2]. Disease manifestations are a
consequence of the accumulation of glycosphingolipids
in lysosomes and extralysosomal and extracellular spaces
[3]. However, the precise cellular and molecular mecha-
nisms linking glycolipid accumulation to tissue injury
and disease manifestation are not fully understood. The
lack of an adequate animal model for the disease has
hindered progress in understanding the pathogenesis
and, development of optimal therapy.
Initial symptoms of Fabry disease usually appear in
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distribution, and reproduction in any mediumthreatening [1]. These include angiokeratoma, neuro-
pathic pain, hypohydrosis and digestive tract symptoms.
During the second decade of life, potentially life-
threatening involvement may develop, including the cen-
tral nervous system (CNS), including stroke, chronic
kidney disease (CKD) usually associated with proteinuria
and progressive loss of glomerular filtration rate (GFR),
and left ventricular (LV) hypertrophy, arrhythmia and
heart failure. Fibrosis of these organs is a key feature of
Fabry disease. Enzyme replacement therapy (ERT) is the
current cornerstone of Fabry disease management [1,4,5]
(Figure 1). ERT is less efficacious when started after the
development of tissue injury and specifically, of tissue fi-
brosis [6]. ERT should be complemented by symptom-
atic therapy and by adjuvant therapy aimed at modifying
the underlying pathogenic mechanisms of tissue injury,
such as targeting the renin-angiotensin-aldosterone sys-
tem (RAAS) to reduce proteinuria [4,5,7]. Novel thera-
peutic approaches based on a better understanding of
pathogenic events are needed to complement ERT and
optimize patient outcomes. In this review we discuss the
current understanding of fibrosis in Fabry disease, andntral Ltd. This is an Open Access article distributed under the terms of the
/creativecommons.org/licenses/by/2.0), which permits unrestricted use,
, provided the original work is properly cited.
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Figure 1 Conceptual framework for the design of novel therapeutic approaches to Fabry disease: lessons from diabetic nephropathy.
A) Pathogenesis of Fabry fibrosis. The traditional view is that this is a late event secondary to endothelial glycolipid deposition leading to luminal
obstruction and ischemia. However, fibrosis in other metabolic disorders, such as diabetes, is known to result from recruitment of secondary
mediators of injury by both direct actions of accumulated metabolites (in this case glucose) on target organ cells and also by ischemia. Recent
evidence suggests that certain metabolites that accumulate in Fabry disease may recruit secondary mediators of injury in target organ cells. Such
pathways might be amenable to therapeutic targeting by preventing the effects of accumulated metabolites on target cell or by targeting the
secondary mediators that are recruited. B) Potential impact on therapy of an improved understanding of the pathogenesis of fibrosis in Fabry
disease. Current therapy of Fabry disease consists of enzyme replacement therapy (ERT). Substrate reduction therapy (SRT) in under investigation
and may further decrease the levels of certain metabolites identified as pro-fibrotic. Identification of metabolites recruiting secondary mediators
of injury may eventually lead to therapies preventing their binding to receptors. In addition, anti-proteinuric therapy may decrease the pro-
inflammatory, pro-fibrotic effects of proteinuria in the kidney. Certain anti-proteinuric agents have additional anti-fibrotic actions in the kidney
and vasculature. Finally, targeting of secondary mediators of fibrosis may further prevent fibrosis progression in patients with more advanced
disease for whom correction of the initial metabolic defect may not be sufficient.
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fibrosis to disease burden in Fabry disease? What are the
cellular and molecular mechanisms of fibrosis? How can
fibrosis be assessed? And what are the prospects for
fibrosis-guided therapy?
Fibrosis as a feature of organ damage
Fibrosis is characterized by an increased accumulation of
extracellular matrix (ECM) [8-11]. Fibrosis or the forma-
tion of scar tissue can be the end-result of tissue injury,
inflammation and apoptosis and might be considered a
final irreversible event with little intrinsic therapeutic
interest [8-11]. However, in some clinical conditions fi-
brosis is an early event, a disease defining-event or a
major contributor to clinical manifestations of disease.
There is evidence that diabetic nephropathy (DN) and
Fabry disease may be such conditions. Like DN, Fabry
nephropathy is a proteinuric nephropathy of metabolic
origin characterized by a progressive decrease of renal
function to a terminal stage requiring dialysis or trans-
plantation. Although the metabolic environments of the
two diseases are considerably different, there is accumu-
lating evidence that they may share common, later-stage
pathogenic pathways with other forms of proteinuric
CKD. Advances in the understanding of fibrosis regula-
tion in prevalent diseases, such as DN, and their thera-
peutic implications may be used to develop therapeutic
approaches to less common conditions like Fabry dis-
ease. In DN intrinsic renal cells are early contributors to
kidney fibrosis. Thus, initial glomerular (GBM) and
tubular basement membrane thickening depends on in-
creased production of ECM by glomerular epithelial
podocytes and tubular epithelial cells injured by high
ambient glucose concentrations [12-15]. This is followed
by recruitment of activated fibroblasts, focal and seg-
mental glomerular fibrosis and sclerosis (FSGS) and
interstitial fibrosis. Interestingly, ECM undergoes remod-
eling and ECM deposits are potentially reversible. Fol-
lowing pancreas transplantation in patients with DN,
increased ECM deposition of metabolic origin is revers-
ible following 10 years of continuous correction of the
metabolic defect, but not after 5 years [16]. ERT pro-
vides clinically significant, but not complete reversal of
the Fabry metabolic defect. Glycolipid deposits may per-
sist for years in certain cell types, such as podocytes, the
key cells in glomerulosclerosis and proteinuria [6,17]
and circulating levels of deacylated globotriaosylceramide
(globotriaosylsphingosine, lyso-Gb3) are reduced but not
normalized by ERT [18-20]. Depending on dose [17], ERT
provides partial control of the metabolic defect in a man-
ner similar to oral anti-diabetic agents and insulin in dia-
betes than to the cure offered by pancreas transplantation.
ERT may be less effective in controlling the metabolic de-
fect due to pre-existent deposits, sub-optimal dose, andantibodies or due to poor tissue penetration. Similarly, dia-
betic patients treated with antidiabetic medications still re-
quire adjuvant, tissue-protective therapies, and a similar
paradigm applies to Fabry disease (Figure 1). Furthermore,
any potential beneficial effect of ERT to ameliorate or re-
verse fibrosis is expected to take many years, especially if
fibrosis is well established before ERT is started.
Fibrosis in Fabry disease
Fibrosis can be found in histological sections of Fabry
disease targets organs. Renal fibrosis is a feature of Fabry
nephropathy. The time-course of kidney fibrosis is not
as clearly established as in DN, but emerging evidence
points to a similar pattern: early podocyte injury and fibro-
sis generated by epithelial cells that increase as disease
progresses [17,21-23] (Figure 2). A grossly thickened GBM
was noted in early reports of Fabry nephropathy and GBM
duplications and increased glomerular mesangial ECM are
also found [21,24-27]. Glomerulosclerosis and interstitial
fibrosis are already present in children with early stage tis-
sue injury characterized by preserved renal function and
albuminuria <300 mg/g creatinine, along with features of
podocyte injury such as segmental foot-process effacement
[17,21]. Glomerular sclerosis and interstitial fibrosis may
also be observed in females with normal renal function
and in the absence of overt proteinuria [23]. In a cross-
sectional study of 59 male and female Fabry patients the
mean percentage of non-sclerosed glomeruli was 82±19%
in 25 patients with well preserved renal function (mean
estimated GFR = 113 ml/min/1.73 m2) and 21±14% in 5
patients with severe CKD (eGFR= 16 ml/min/1.73 m2).
Mean percentage of interstitial fibrosis area was 8±16%
and 66±14%, respectively [22].
The typical clinical presentation of Fabry cardiomyop-
athy is LV hypertrophy. Most patients with a cardiomy-
opathy exhibit a concentric LV hypertrophy with an
end-diastolic wall thickness of up to 16 mm without
concomitant LV outflow tract obstruction [28]. Typical
features of Fabry cardiomyopathy include prominence
of the papillary muscle [29-31] and development of re-
placement fibrosis in the basal postero-lateral segments
[32-34]. In addition, biopsies have shown interstitial
fibrosis at early cardiomyopathy stages. The fibrotic
process starts in the mid-myocardial layers and spreads
with disease progression towards transmural fibrosis.
Thus, the end-stage of the cardiomyopathy is character-
ized by the co-existence of LV hypertrophy, myocardial
thinning, and the presence of wall motion abnormalities
in the fibrotic segments [35,36].
In female Fabry patients, LV hypertrophy and fibrosis
seems to be not tightly linked [37], perhaps reflecting
the residual alpha galactosidase A activity in females. Re-
placement fibrosis can already be present at a non-
hypertrophic disease stage, which is in contrast to males
A)
B)
Figure 2 Kidney biopsy. A) PAS staining. Histology of the kidney with characteristic changes of advanced Fabry nephropathy. Please note
glomerular segmental sclerosis (A), adhesion and Bowman capsule reduplication (B), tubular atrophy and tubular cell related fibrosis (thickened
basement membranes) (C) and arteriolar hyalinosis (D). Original magnification 63×. Courtesy of Prof. Justus Müller, Department of Pathology,
University Hospital of Würzburg, Würzburg, Germany. B) Sirius red staining of collagen fibers illustrates peri-glomerular fibrosis (E) and interstitial
fibrosis (F). Original magnification × 20.
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quent replacement fibrosis. In addition, in all female pa-
tients who develop LV hypertrophy, replacement fibrosis
is present. Thus, despite the delayed development of LV
hypertrophy, fibrosis seems to progress continuously
and is an integral component of the cardiomyopathy
[37] in female patients with Fabry disease.
Much less is known about fibrosis of the CNS in Fabry
disease. Indeed the general pathogenesis of fibrosis inthe CNS is poorly understood. The term gliosis or glial
reaction indicates structural and physiological changes
of astrocytes and microglia in response to ischemic,
inflammatory or traumatic injuries to the CNS. A prom-
inent feature of gliosis is the proliferative response to
injury that is followed later by permanent changes, the
glial scar [38]. Gliosis is known to occur in the penum-
bra area adjacent to the ischemic core during stroke
[39]. In Fabry disease gliosis and fibrosis have been
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ondary to ischemic encephalopathy included fibrillar
astrocytosis and proliferation of microglia adjacent to
pyknotic neurons in the hippocampus, cerebral cortex
and white matter [40]. In addition, features of a more
generalized fibrotic process were also observed in Fabry
disease, such as thickening of the pia-arachnoid mem-
branes and an angiopathy of the subarachnoidal arteries
characterized by intima and medial thickening and fibro-
sis and adventitial fibrosis associated with gliosis [25,41].
Pathogenesis of fibrosis in Fabry disease
Improved understanding of fibrosis in Fabry disease will
permit development of more effective therapeutic ap-
proaches to Fabry disease. “Fabry mice” (GLA −/− and -
/0 mice) display mild accumulation of glycosphingolipids
but have thus far failed to develop significant kidney
or heart disease [42]. The lack of significant end-
organ fibrosis may be due to a lower accumulation of
glycosphingolipids in mice, differences in lipid metabol-
ism between mice and humans, the potential need for
several years of progressive glycolipid accumulation and
the genetic background of current Fabry mouse models.
In the absence of an adequate animal model only
hypothesis based on human histology or cell culture
models are available. Previous reports emphasized that
the histological appearance of advanced Fabry nephropa-
thy suggested that kidney fibrosis was a consequence of
ischemia [24,26]. Thus, in 25 to 50 year old patients,
glomerulosclerosis, often with wrinkled and partially col-
lapsed GBM, tubular atrophy and interstitial fibrosis
were thought to result from the also present vascular
thickening. However, these are non-specific features of
advanced kidney disease of any etiology. Moreover, these
changes were generally minimal in patients <25 years,
further supporting the notion that these are secondary
features of the disease and that early pathogenic events
may differ. At that time the key importance of podocytes
in the maintenance of the glomerular filtration barrier to
proteins and the pathogenesis of glomerulosclerosis was
unknown. It is now widely accepted that podocyte injury
is a key event in the development of proteinuric kidney
disease, and that podocyte loss is the main driver of
glomerulosclerosis [12]. More recently it has been recog-
nized that podocytes are among the earliest cells to be
loaded with glycolipid deposits. Moreover, podocyte de-
posits volume density increased progressively with age
(unlike endothelial or mesangial inclusion volume dens-
ities). Foot process width was greater in male Fabry
patients and progressively increased with age compared
with the controls, and correlated directly with protein-
uria [43]. Finally, podocyte effacement, a manifestation
of podocyte injury, is observed in children with minimal
albuminuria [21]. Hence, podocyte injury has beenproposed to play a pivotal role in the development and
progression of Fabry nephropathy [43]. In this regard,
podocyte deposits are the less responsive to ERT in
adults and may take up to 5 years of continued ERT to
show significant clearing [6,17,44]. The clinical correlate
is lack of improvement of proteinuria by ERT in adults.
By contrast, kidney endothelial cells and fibroblasts de-
posits are cleared within 6–12 months of 1 mg/kg/2
weeks ERT [44]. More support for the concept of a key
role of podocytes in Fabry nephropathy and the need
of clearance of podocyte deposits comes from the ob-
servation that in young patients podocytes can be
cleared by several years of ERT at 1 mg/kg/2 weeks,
and this was associated with regression of “micro-al-
buminuria” [17]. In addition to potential direct effects
of glycolipids on tubular cells, proteinuria itself may
lead to tubular cell activation, inflammatory responses
and interstitial fibrosis.
In cardiomyocytes, GL-3 storage, trophic factors and
other factors (e.g. lyso-Gb3) and ischemia at the microcir-
culatory level are supposed to directly cause injury and
alter the expression of signaling molecules [18,45,46], trig-
gering inflammation, hypertrophy, apoptosis, increased
deposition of extracellular matrix (early interstitial fibro-
sis), and late cell-replacement fibrosis [33,47,48]. The ele-
vated lyso-Gb3 in plasma of symptomatic patients might
partially explain the finding by Barbey et al. [49] of an un-
identified substance in plasma of symptomatic Fabry dis-
ease patients that stimulates proliferation of vascular
smooth muscle cells and cardiomyocytes in vitro. Of note,
a correlation was observed between left ventricular hyper-
trophy and plasma lyso-Gb3 concentration in heterozy-
gote Fabry patients [18]. In addition, it was speculated that
wall stress may contribute to Fabry cardiomyopathy. Thus,
slightly increased blood pressure and the flat curvature
of the basal part of the lateral wall may account for an
increased wall stress that promotes fibrosis. This sce-
nario would account for fibrosis that starts in the endo-
cardium (where wall stress is highest) but not at the
mid-myocardium as is seen in the cardiac involvement
in Fabry disease [50]. Thus, other unknown factors are
contributing to hypertrophy and fibrosis. The relative
contribution of cardiomyocytes versus other cell types
to myocardial fibrosis in Fabry disease is unclear.
It has long been thought that CNS gliosis in Fabry re-
sults from ischemia. The anatomical location of white
matter lesions also supports an ischemic origin, although
the mechanisms of ischemia remain unclear [51,52].
Brain white matter is localized below the cortex and
contains axons from neurons. White matter lesions are
defined by the presence of bright spots (T2 and FLAIR
sequences) in this region in brain imaging. Perfusion
of the white matter depends on the long penetrating
arteries originating from the cortical surface that are
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myelinated fibers. Because there are minimal or no anas-
tomoses between sub-ependimal vessels and vessels ori-
ginating from the cortex, watershed periventricular areas
are susceptible to ischemic injury from decreased cere-
bral blood flow [53]. However, the decreased blood flow
does not result from the involvement of intracerebral
vessels by the glycolipid storage process, and other (as
yet unidentified) hemodynamic factors might also be in-
volved. Khan described massive dilatation of the verte-
bral and basilar arteries in autopsies, but absence of
glycolipid deposits in intracerebral vessels, despite the
marked thickening of the media of small arteries and ar-
terioles caused by deposition of the glycolipid observed
in almost every tissue, including the leptomeninges of
the brainstem and spinal cord [25]. This was true even
in a patient with previous brain infarcts [25]. Whether
other factors contribute to gliosis in the Fabry CNS is
unknown. Recent studies suggest that activated astro-
cytes, marrow-derived fibrocytes and alternatively acti-
vated M2 microglia and macrophages contribute to
non-Fabry CNS fibrosis [54,55]. These factors should be
studied in the context of Fabry disease.
The potential role in fibrosis of additional secondary
biochemical processes found in Fabry disease has not
been addressed [56]. Compromised energy metabolism
has been found both in vitro and in vivo. Low levels of
high-energy phosphate molecules phosphocreatine and
adenosine triphosphate (ATP) were observed in Fabry
patient hearts and improved with ERT [57]. Parameters
of cardiac energy metabolism negatively correlated with
progression of Fabry cardiomyopathy [58]. Low glucose
utilization was observed locally in 18 brain structures in
the alpha-galactosidase A gene knockout mouse [59]. In
this regard, low activities of mitochondrial respiratory
chain enzymes I, IV, and V were lower in cultured Fabry
patient fibroblasts and ATP was marginally reduced [60].
In addition, altered lipid composition of membranes
leading to abnormal trafficking and sorting of rafts-
associated proteins was observed in fibroblasts [61].
In search of the mediators of fibrosis in Fabry
disease: a potential role for lyso-Gb3
Recently, lyso-Gb3 has been proposed as a promoter of
fibrosis in Fabry disease [62]. Having lost a fatty acid,
lyso-Gb3 is more water soluble than Gb3 and in some
aspects it may behave as an accumulated soluble medi-
ator in a similar manner to glucose and its degradation
products that are increased in diabetes. Key differences
between lyso-Gb3 and glucose and its degradation prod-
ucts should be recognized; the latter may react with and
modify proteins such as type IV collagen in the GBM. In
this regard, the fact that some molecular mechanisms of
fibrosis may be similar in Fabry disease and DN cannotbe construed as a general equivalence of the underlying
pathogenesis.
Plasma lyso-Gb3 is dramatically increased in classically
affected male Fabry patients, but is also increased in fe-
males and is reduced but not normalized following ERT
while it is undetectable in normal human plasma
[18-20]. These characteristics may contribute to a cross-
talk between cells with persistent glycolipid deposits fol-
lowing ERT and may explain observations such a similar
mean age at end-stage renal disease for males and for fe-
males [63,64]. In this regard, concentrations of lyso-Gb3
observed in plasma of females or ERT-treated Fabry
males are biologically active in target cells of Fabry
disease in culture even when these cells possess alpha-
galactosidase activity [18,62]. Lyso-Gb3 promoted prolifer-
ation of vascular smooth muscle cells, but not fibroblasts
[18]. In addition, in cultured human podocytes, lyso-Gb3
recruited secondary mediators of inflammation and fibro-
sis. Thus, in normal human podocytes lyso-Gb3 dose-
and time-dependently increased the expression of the
fibrogenic cytokine TGF-β1 and increased ECM (fibronec-
tin and type IV collagen) synthesis in a TGF-β1-dependent
manner [62]. The fibrogenic response of podocytes to
lyso-Gb3 is similar to podocyte responses to a high glu-
cose extracellular milieu [13]. Furthermore, lyso-Gb3
stimulated inflammation similar to high glucose levels
does, promoting the expression of the cytokine receptor
CD74 [62,65,66]. Lifetime exposure to lysoGb3 correlated
with disease manifestations [67]. Plasma lysoGb3 con-
centration correlated with white matter lesions. In fe-
males, plasma lysoGb3 concentration correlated with
overall disease severity and LV mass. In addition,
lyso-Gb3 reduction on ERT was correlated with LV
mass reduction in females and development white
matter lesions and stroke [68].
Clinical consequence of fibrosis and non-invasive
assessment of fibrosis in Fabry disease
Imaging techniques in the heart and brain, but not in
the kidney can non-invasively assess fibrosis in Fabry
disease. In addition, clinical manifestations associated
with fibrosis may provide an approximate idea of the ex-
tent of underlying fibrosis.
Currently, renal biopsy provides the best assessment
of the degree of kidney fibrosis. However, fibrosis may
be patchy and the biopsy may not always be fully repre-
sentative of the whole kidney. Imaging does not yet pro-
vide a sensitive assessment and monitoring of kidney
fibrosis in humans. Advanced magnetic resonance im-
aging (MRI) devices allow quantification of renal fibrosis
in experimental animals and clinical advances in the
field are expected in the near future. MRI or ultrasound
identify abnormalities suggestive of kidney fibrosis such
as increased echogenicity, decreased cortical thickness
Figure 3 Cardiac fibrosis. A magnet resonance imaging short axis
view of a 54-year-old male Fabry patient. The arrow indicates the
late enhancement positive region of the left ventricle.
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classically affected males with serum creatinine levels
<1.3 mg/dL pointing to kidney fibrosis preceding a de-
crease in renal function [69]. Urinary protein/creatinine
ratio >1g/g, eGFR <45 ml/min/1.73m2 or biopsy-proven
glomerulosclerosis are associated with progressive kid-
ney disease or a sub-optimal response to ERT [6,70,71],
suggesting that these non-invasive biochemical assess-
ments provide insights into both the underlying tissue
pathology and response to ERT. Indeed, proteinuria is a
known consequence of glomerulosclerosis. However, in-
dividual variability and the presence of functional factors
that impact on albuminuria and proteinuria or GFR
makes unreliable the estimation of the degree of kidney
fibrosis from biochemical parameters. Clearly, improved
imaging methods or biomarkers are needed to reliably,
repetitively and non-invasively assess kidney fibrosis.
Cardiac fibrosis can be visualized either directly using
MRI with the late enhancement (LE) technique, or in-
directly using functional deformation imaging [32,34]
(Figure 3). The gold standard for assessing replacement
cardiac fibrosis is late enhancement (LE) imaging dur-
ing MRI [32,50]. As the distribution of LE positive vol-
ume is more localized and not as patchy as in other
cardiac diseases it is possible to quantify the LE positive
volume in relation to the LV mass with advanced MRI
techniques. In a large cohort study, 51% of the Fabry
patients (female 44.1%; male 61.9%) showed mid- and
trans-myocardial LE with a mean volume of 1.2±1.8%
of the LV mass [72]. Female patients with LE positive
myocardium presented smaller volumes of LE (0.8
±1.3%) than male patients (1.6±2.3%). In a more ad-
vanced population even 7.7% of the LV mass was LE
positive [32]. In general in both genders, pathologicalLE is mostly limited to posterior and lateral segments,
with different distensions towards the apex but not
reaching the apical segments. However, these MRI
measurements cannot be performed in all Fabry pa-
tients; for patients with end-stage renal disease contrast
agents are contraindicated, and MRI examinations
cannot be carried out on patients with an implanted
cardiac devices or pacemakers [73]. Therefore, other
echocardiographic techniques like speckle tracking and
strain rate imaging may be useful in these patients for
the indirect assessment of replacement fibrosis. Obvi-
ously, fibrosis has an impact on myocardial function.
When applying tissue Doppler based deformation im-
aging the strain rate curves extracted from the segment
with replacement fibrosis present with a typical double
peak sign [74]. Use of this sign allows a qualitative but
not a quantitative evaluation for fibrosis of the interro-
gated segment [73]. As this technique is time consum-
ing and difficult for post processing new imaging
techniques like 2D speckle tracking are being devel-
oped to assess functional abnormalities. This technique
can be applied for the non-invasive evaluation of LE re-
lated functional abnormalities in patients with Fabry
disease. It is widely available, highly reproducible and
easily applicable in most patients. Although a direct
quantification of the amount of fibrosis is not possible,
a systolic longitudinal strain value >16.5% in the typical
postero-lateral region makes replacement fibrosis ex-
tremely unlikely [72]. Vice versa, a value <12.5% is very
often related to replacement fibrosis and results in the
diagnosis of advanced fibrotic stage of the disease. As
the evaluation of replacement fibrosis is crucial for sta-
ging of the cardiomyopathy, every adult patient should
receive a MRI at least once. This is especially important
in female patients, because the only sign of cardiomy-
opathy can be the fibrosis in the postero-lateral wall.
Early interstitial fibrosis might have an impact on glo-
bal systolic and diastolic function but can not directly
visualized. MRI based new T1 mapping techniques
might be of value for indirect detection of early inter-
stitial fibrosis. However, this is still under investigation.
Replacement heart fibrosis may result in heart failure
or arrhythmia, including brady-arrhythmias and malig-
nant ventricular arrhythmias [36,75].
In the central nervous system white matter lesions
(leukoaraiosis) characterized by bilateral and either
patchy or diffuse areas of hyperintensity on T2-weighted
MRI are a feature of Fabry disease (Figure 4). To what
extent they represent gliosis or other features of CNS
injury; such as patchy demyelination in Fabry disease is
unknown. Studies are needed on the potential relation-
ship to early gliosis of metabolic abnormalities found by
proton MR spectroscopic imaging (H-MRSI), Diffusion-
Tensor-Imaging (DTI) or 18 fluorodeoxyglucose PET
Figure 4 Central nervous system white matter lesions. 45-year
-old male. T2 Brain MR image showed widespread, punctuated and
confluent white matter lesions from periventricular to subcortical
spaces. These lesions are associated with severe axonal
injury (gliosis).
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in Fabry patients [76-81]. Brain levels of N-acetylaspartate
(NAA), an aminoacid localized almost exclusively in neu-
rons and axons in mature brain that correlates with axonal
density, were lower in Fabry patients than in normal
controls when assessed by H-MRSI [76,79]. DTI measures
the random translational motion of water molecules
as mean diffusivity (MD). Global mean MD values were
higher in Fabry patients than in controls [77,80]. 18
fluorodeoxyglucose PET disclosed decreased glucose uti-
lization in some deep and periventricular white matter re-
gions even in the absence of lesions [81]. Politei and
Capizzano reported significantly increased mean apparent
diffusion coefficient values in posterior paraventricular
white matter regions in Fabry patients despite no evident
white matter lesions in MRI [78] DTI is useful to predict
progression of microvascular injury and eventual develop-
ment of gliosis in patients at high cardiovascular risk.
Stepwise decreases in white matter integrity as measured
by both DTI and FLAIR were associated with stepwise in-
creases in white matter lesions risk, emphasizing that
these modalities may provide complementary information
for understanding the time course of neuronal and axonal
degeneration [82]. Additional studies should test whether
these results apply to Fabry disease. No obvious relation-
ship was found between MRI white matter lesions and
neuropsychiatric symptoms in Fabry patients [83].Beyond ERT: management of fibrosis in Fabry
disease
The assessment of fibrosis has impact on management
and on response to therapy. ERT is the standard therapy
for Fabry disease. ERT partially cleared microvascular
deposits of GL-3 from the heart, kidney and skin of
most Fabry patients [46,84-86]. However, deposits in
podocytes may persist for years in adults [6,17]. GL-3
clearance from the myocardium and kidney concurs
with a decrease of LV mass and an improvement of re-
gional myocardial function and stabilizes renal function
if started early [6,34,74,87,88]. In contrast, ERT may be
less effective in the presence of tissue fibrosis identified
either by the presence of glomerulosclerosis in renal bi-
opsy, by surrogate markers of kidney fibrosis such as
proteinuria >1g/d or an eGFR< 45 ml/min or by evi-
dence of replacement fibrosis in LV [5,6,70,71]. Thus
even with ERT, the annual progression of LV replace-
ment fibrosis is 0.7±0.7% in males and 0.2±0.3% in fe-
males [89], emphasizing the need to understand the
molecular mechanism and optimize anti-fibrotic therapy.
This has two clinical implications: a) Before starting with
ERT a baseline staging of the extent of fibrosis should be
obtained in all patients for adjusting outcome expecta-
tions. Disease stabilization is unlikely in the presence of
fibrosis. b) Add-on therapies targeting fibrosis may be
beneficial in patients with evidence of fibrosis. These
add-on therapies are expected to be used in addition to
ERT or to any other treatments aimed at correcting the
metabolic defect that are developed, such as chaperones
or substrate reducing therapy. Ideally clinical trials
should address the safety and efficacy of these ap-
proaches in Fabry disease. However, clinical trials of
these add-on therapies are unlikely given the low fre-
quency of the disease. Until we have clinical trial data,
we have to rely on extrapolating concepts that have
proven beneficial in other forms of CKD or cardiac fi-
brosis. In addition, special attention should be paid to
elucidating the mechanisms of generation and actions of
suspected pro-fibrotic molecules such as lyso-Gb3 as
well as in characterizing their receptors, since limiting
their production or preventing their pro-fibrotic action
might be beneficial in Fabry disease.
The standard of treatment of proteinuric CKD, includ-
ing DN and FSGS, involves anti-proteinuric therapy
with drugs targeting the RAAS such as angiotensin
converting enzyme inhibitors (ACEi) or angiotensin re-
ceptor blockers (ARBs) [90,91]. Components of the
RAAS have direct pro-fibrotic effect that can be demon-
strated in cultured cells and animal models in diverse
organs that can be prevented by ACEIs, ARBS and anti-
aldosterone agents, suggesting a general profibrotic
effect of the RAAS beyond specific roles in the biology
of specific organs [92,93]. In Fabry nephropathy the
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proteinuria prevented progression of CKD in patients
with baseline estimated GFR <60 ml/min/1.73 m2 [7].
An ongoing clinical trial is validating this clinical obser-
vation (The FabrazymeW and Arbs and ACE Inhibitor
Treatment (FAACET) Study [94]. However, neither
study assessed renal fibrosis. Meanwhile RAAS targeting
is recommended to lower proteinuria in Fabry disease,
in association to ERT [4]. Furthermore, RAAS targeting
is also beneficial in chronic cardiomyopathies. Fabry
patients with a fibrotic cardiomyopathy generally require
comprehensive management of hypertension with
angiotensin-converting enzyme inhibitors and ß-adren-
ergic blocking agents, in addition to ERT [7,95]. A pace-
maker implantation might be necessary in cases with
symptomatic bradycardia [75]. In addition, patients with
late-stage cardiomyopathy who develop life threatening
arrhythmias should be evaluated for and eventually pro-
vided with insertion of an implantable-cardio-defibrilla-
tor (ICD), in addition to pharmacological therapy and
ERT [95].
The cell culture observations on the pro-fibrotic role of
lyso-Gb3 may have practical therapeutic consequences. In
this regard, vitamin D receptor activation with paricalcitol
or calcitriol prevented the increase in TGF-β1, CD74 and
ECM induced by lyso-Gb3, suggesting that vitamin D re-
ceptor (VDR) activation is a potential adjunctive therapy
in Fabry nephropathy [62]. A recent clinical trial found in-
conclusive evidence of an anti-proteinuric effect of the
VDR activator paricalcitol in DN [96]. In addition VDR
activation has anti-proteinuric and anti-fibrotic effects in a
variety of animal models of kidney injury and may also im-
prove LV hypertrophy [97], although the latter was not
confirmed in a clinical trial [98]. Guidelines for the general
population and CKD patients suggest that vitamin D defi-
ciency should be corrected [91]. Thus, it seems advisable
to place particular emphasis in following guidelines on
vitamin D management in CKD patients in patients with
Fabry disease [5]. Furthermore, specific targeting of mo-
lecular mediators of fibrosis such as TGFβ1 is undergoing
clinical trials for FSGS [99]. TGFβ1 is a key fibrogenic
cytokine [9-11] and was recently found up regulated the
enlarged heart of a patient with mucopolysaccharidosis
type I (deficiency of α-L-iduronidase) who died from
sudden cardiac failure [100]. The mucopolysaccharidoses
(MPS) are a group of lysosomal storage disorders (LSD)
due to deficiency of enzymes involved in the catabolism of
glycosaminoglycans. Like Fabry disease, all types of MPS
(particularly MPS-I, II and VI) can present with cardiovas-
cular manifestations, including hypertrophic cardiomyop-
athy, thickened valvular lesions, and coronary artery
lesions. Therefore, it might postulated, and worth testing
the hypothesis, that TGF β1 signaling hyperactivity is a
pathogenic event common to LSD affecting the heart.Additional mediators of fibrosis undergoing clinical trials
for other indications include the Notch system of ligands
and receptors [101] and another member of the RAAS, al-
dosterone [102,103].
A tight control of cardiovascular risk factors, including
the use of statins is recommended in Fabry disease.
Statins have been reported to have anti-fibrotic activity
in kidneys, the vasculature and the heart [104-107]. To-
gether with RAAS targeting, statins have been studied as
upstream therapy for atrial fibrillation, that is, the use of
non-antiarrhythmic drugs to modify the atrial substrate-
or target-specific mechanisms of atrial fibrillation, such
as atrial fibrosis, hypertrophy or inflammation [108].
Their potential contribution to the treatment of Fabry fi-
brosis should be studied.
In conclusion, fibrosis of target organs is an early
event in the course of Fabry disease and indicates an im-
paired response to ERT. A better understanding of the
molecular mechanisms of fibrosis may pave the way for
the design of add-on therapeutic strategies that improve
patient outcomes. Ideally these strategies should be
tested in clinical trials.
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